Event-Driven Stocks

Bioventus Inc.

BVSNasdaq

Healthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs3 good1 warning2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$568.1M$573.3M$512.3M$512.1M$430.9M$321.2M
Operating income$54.0M−$15.2M−$81.7M−$167.2M$12.1M$21.2M
Net income$22.7M−$36.1M−$156.2M−$158.7M$19.4M$16.4M
Total assets$683.6M$728.0M$810.9M$1.37B$1.23B$494.5M
Total liabilities$455.1M$542.4M$589.8M$960.4M$618.2M$350.3M
Equity$184.1M$147.9M$173.6M$325.2M$458.9M
EPS (diluted)$0.33$-0.56$-2.49$-2.59$-0.15
Shares out.68.9M64.5M62.6M61.4M45.5M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
9.5%
Net margin
4.0%
Return on equity
12.3%
Return on assets
3.3%
Return on capital (ROCE)
10.3%
Liabilities / assets
66.6%
Debt / equity
2.47×
Book value / share
$2.67
Revenue growth (YoY)
−0.9%
Net income growth (YoY)

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
0.44distress
Accruals / assets
7.6%clean
Piotroski F-Score
8/9strong

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
57
/ 100
Profitability 100Growth 0Catalyst 33Earnings quality 100Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

2 severe1 warning3 good
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Revenue declined year-over-year
  • Operating margin is positive
  • Positive operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
11 acquisitions1 disposalsnet +130,699 shares · last 12
InsiderDateTypeSharesPrice
Singleton Mark LeonardOfficer — SVP &amp; CFOApr 10, 2026Option exercise13,000$0.00
Church Katrina JOfficer — SVP &amp; Chief Compliance OfficerApr 10, 2026Option exercise4,300$0.00
D'Adamio AnthonyOfficer — SVP &amp; General CounselApr 10, 2026Option exercise9,925$0.00
Singleton Mark LeonardOfficer — SVP &amp; CFOMar 20, 2026Option exercise18,625$0.00
Singleton Mark LeonardOfficer — SVP &amp; CFOMar 13, 2026Option exercise13,500$0.00
Church Katrina JOfficer — SVP &amp; Chief Compliance OfficerMar 13, 2026Option exercise3,455$0.00
D'Adamio AnthonyOfficer — SVP &amp; General CounselMar 13, 2026Option exercise8,886$0.00
Claypoole Robert EOfficer — President and CEOMar 13, 2026Option exercise33,500$0.00
Mcmurry-Heath MichelleDirectorMar 11, 2026Sell12,000$8.79
Singleton Mark LeonardOfficer — SVP &amp; CFOFeb 15, 2026Option exercise20,153$0.00
Church Katrina JOfficer — SVP &amp; Chief Compliance OfficerFeb 15, 2026Option exercise4,375$0.00
D'Adamio AnthonyOfficer — SVP &amp; General CounselFeb 15, 2026Option exercise12,980$0.00

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20261.6M2.9+7.5%
Apr 30, 20261.5M3.4+8.7%
Apr 15, 20261.3M3.1-12.1%
Mar 31, 20261.5M3.0+7.7%
Mar 13, 20261.4M3.2-0.8%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.